Overview Dividends

(ELAN) Elanco Animal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28414H1032

Parasiticides, Vaccines, Therapeutics, Antibiotics, Feed Additives

ELAN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 0.00%
EPS Trend (3Y Correlation): 0.5%

ELAN Revenue

Revenue Growth (3Y CAGR): 5.24%
Revenue Trend (3Y Correlation): 29.9%

Risk via 10d forecast
Volatility	43.4%
Value at Risk 5%th	72.1%
Relative Tail Risk	-18.11%

Reward TTM
Sharpe Ratio	0.94
Alpha	32.94

Character TTM
Hurst Exponent	0.492
Beta	1.255
Beta Downside	1.246

Drawdowns 3y
Max DD	56.10%
Mean DD	20.67%
Median DD	21.31%

Description: ELAN Elanco Animal Health November 03, 2025

Elanco Animal Health (NYSE: ELAN) develops, manufactures and markets a broad portfolio of veterinary products for companion animals and livestock. Its pet-care line includes parasiticides, vaccines and therapeutics sold under brands such as Seresto, Advantix, Credelio, Galliprant and Atopica, while its farm-animal segment offers medicated feed additives, injectable antibiotics, vaccines and insecticides for cattle, swine and poultry (e.g., Rumensin, Baytril, Maxiban, AviPro). Distribution is a mix of third-party wholesalers, independent retailers and direct sales to veterinarians and producers.

Key metrics that shape Elanco’s outlook include FY 2023 revenue of roughly $3.2 billion, with the pet-health segment contributing about 55 % and delivering a 12 % YoY growth rate driven by rising pet ownership and premiumization trends in the United States and Europe. The livestock business is sensitive to global protein demand; a 5 % annual increase in meat consumption in emerging markets is a primary growth driver, while feed-cost inflation and regulatory scrutiny on antibiotic use pose margin pressures. Elanco’s R&D pipeline, highlighted by next-generation parasiticides and a pipeline of novel biologics for dairy cattle, is expected to sustain product-launch momentum over the next 12-24 months.

For a deeper, data-driven valuation of ELAN, you may find ValueRay’s analyst toolkit useful for quantifying these drivers and testing scenario outcomes.

ELAN Stock Overview

Market Cap in USD	10,926m
Sub-Industry	Pharmaceuticals
IPO / Inception	2018-09-20
Return 12m vs S&P 500	31.1%
Analyst Rating	3.87 of 5

ELAN Dividends

Currently no dividends paid

ELAN Growth Ratios

CAGR 3y	21.20%
CAGR/Max DD Calmar Ratio	0.38
CAGR/Mean DD Pain Ratio	1.03
Current Volume	5268.8k
Average Volume	5525.2k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (36.0m TTM) > 0 and > 6% of Revenue (6% = 275.5m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 44.39% (prev 45.91%; Δ -1.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 629.0m > Net Income 36.0m (YES >=105%, WARN >=100%)

Net Debt (3.52b) to EBITDA (891.0m) ratio: 3.95 <= 3.0 (WARN <= 3.5)

Current Ratio 2.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (496.8m) change vs 12m ago -0.18% (target <= -2.0% for YES)

Gross Margin 46.37% (prev 42.68%; Δ 3.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.22% (prev 33.53%; Δ 0.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.93 (EBITDA TTM 891.0m / Interest Expense TTM 237.0m) >= 6 (WARN >= 3)

Altman Z'' 0.31

(A) 0.15 = (Total Current Assets 3.49b - Total Current Liabilities 1.46b) / Total Assets 13.55b

(B) -0.14 = Retained Earnings (Balance) -1.91b / Total Assets 13.55b

(D) -0.31 = Book Value of Equity -2.10b / Total Liabilities 6.80b

Total Rating: 0.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 45.60

1. Piotroski 3.50pt = -1.50

2. FCF Yield 2.51% = 1.25

3. FCF Margin 7.88% = 1.97

4. Debt/Equity 0.60 = 2.33

5. Debt/Ebitda 3.95 = -2.50

6. ROIC - WACC (= -6.61)% = -8.27

7. RoE 0.55% = 0.05

8. Rev. Trend 29.88% = 2.24

9. EPS Trend 0.46% = 0.02

What is the price of ELAN shares?

As of November 16, 2025, the stock is trading at USD 21.09 with a total of 5,268,778 shares traded.
Over the past week, the price has changed by -1.86%, over one month by +4.30%, over three months by +17.17% and over the past year by +50.21%.

Is Elanco Animal Health a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Elanco Animal Health (NYSE:ELAN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 45.60 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELAN is around 20.07 USD . This means that ELAN is currently overvalued and has a potential downside of -4.84%.

Is ELAN a buy, sell or hold?

Elanco Animal Health has received a consensus analysts rating of 3.87. Therefore, it is recommended to buy ELAN.

Strong Buy: 6
Buy: 1
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ELAN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	23.8	12.9%
Analysts Target Price	23.8	12.9%
ValueRay Target Price	22.3	5.6%

ELAN Fundamental Data Overview November 15, 2025

Market Cap USD = 10.93b (10.93b USD * 1.0 USD.USD)
P/E Trailing = 314.1429
P/E Forward = 22.0264
P/S = 2.3799
P/B = 1.6233
P/EG = 4.0091
Beta = 1.867
Revenue TTM = 4.59b USD
EBIT TTM = 221.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 3.96b USD (from longTermDebt, last quarter)
Short Term Debt = 62.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.52b USD (from netDebt column, last quarter)
Enterprise Value = 14.45b USD (10.93b + Debt 4.02b - CCE 505.0m)
Interest Coverage Ratio = 0.93 (Ebit TTM 221.0m / Interest Expense TTM 237.0m)
FCF Yield = 2.51% (FCF TTM 362.0m / Enterprise Value 14.45b)
FCF Margin = 7.88% (FCF TTM 362.0m / Revenue TTM 4.59b)
Net Margin = 0.78% (Net Income TTM 36.0m / Revenue TTM 4.59b)
Gross Margin = 46.37% ((Revenue TTM 4.59b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 53.39% (prev 46.49%)
Tobins Q-Ratio = 1.07 (Enterprise Value 14.45b / Total Assets 13.55b)
Interest Expense / Debt = 1.29% (Interest Expense 52.0m / Debt 4.02b)
Taxrate = 32.0% (-16.0m / -50.0m)
NOPAT = 150.3m (EBIT 221.0m * (1 - 32.00%))
Current Ratio = 2.40 (Total Current Assets 3.49b / Total Current Liabilities 1.46b)
Debt / Equity = 0.60 (Debt 4.02b / totalStockholderEquity, last quarter 6.75b)
Debt / EBITDA = 3.95 (Net Debt 3.52b / EBITDA 891.0m)
Debt / FCF = 9.72 (Net Debt 3.52b / FCF TTM 362.0m)
Total Stockholder Equity = 6.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 36.0m / Total Assets 13.55b)
RoE = 0.55% (Net Income TTM 36.0m / Total Stockholder Equity 6.49b)
RoCE = 2.11% (EBIT 221.0m / Capital Employed (Equity 6.49b + L.T.Debt 3.96b))
RoIC = 1.40% (NOPAT 150.3m / Invested Capital 10.73b)
WACC = 8.01% (E(10.93b)/V(14.95b) * Re(10.64%) + D(4.02b)/V(14.95b) * Rd(1.29%) * (1-Tc(0.32)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
[DCF Debug] Terminal Value 65.43% ; FCFE base≈369.2m ; Y1≈305.0m ; Y5≈220.9m
Fair Price DCF = 5.52 (DCF Value 2.74b / Shares Outstanding 496.9m; 5y FCF grow -20.95% → 3.0% )
EPS Correlation: 0.46 | EPS CAGR: 0.0% | SUE: 1.48 | # QB: 3
Revenue Correlation: 29.88 | Revenue CAGR: 5.24% | SUE: 2.58 | # QB: 3

Additional Sources for ELAN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle